Cytomegalovirus Cell Mediated Immunity

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Cytomegalovirus Cell Mediated Immunity trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT06639854

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Ce…

The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transpla…

United States105 participantsStarted 2024-11-20

Treatment: Hematopoietic Cell Transplant, Letermovir

All recent trials (18 shown)

Not Yet RecruitingNot Applicable

NCT06814301

Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalov…

Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) p…

Spain123 participantsStarted 2025-12-01

Treatment: Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV, Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV

TerminatedNot Applicable

NCT02064699

Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®…

Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D +…

France75 participantsStarted 2013-05

Cytomegalovirus Cell Mediated Immunity

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Ce…

All recent trials (18 shown)

Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalov…

Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Ce…

All recent trials (18 shown)

Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalov…

Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®…

Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

Cell-mediated Immunity for Prevention of CMV Disease

Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclo…

Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients,…

Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients

Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients

Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Tran…

Cytomegalovirus Cell-Mediated Immunity

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients

Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress

Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections

Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction